Ginkolide B

Ginkolide B

SCHEMBL12714280

C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@]36[C@@H](OC(=O)[C@@H]6O)O[C@@]4(C(=O)O5)[C@@]12O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PTAFR P25105 4/20 1.00
GLRA1 P23415 3/20 1.00
GLRA2 P23416 3/20 1.00
CYP2C9 P11712 1/20 1.00
HSD17B10 Q99714 1/20 1.00
GUSB P08236 1/20 1.00
KMT2A Q03164 2/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
MEN1 O00255 1/20 0.67
KDM4E B2RXH2 1/20 0.66
MAPK1 P28482 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ginkolide B SCHEMBL13702797 1.00 PTAFR (1.00) PTAFRGLRA1GLRA2CYP2C9HSD17B10
Ginkolide B SCHEMBL464784 1.00 PTAFR (1.00) PTAFRGLRA1GLRA2CYP2C9HSD17B10
Ginkolide B SCHEMBL29495629 1.00 PTAFR (1.00) PTAFRGLRA1GLRA2CYP2C9HSD17B10
Ginkolide B SCHEMBL16407904 1.00 PTAFR (1.00) PTAFRGLRA1GLRA2CYP2C9HSD17B10
Ginkolide B SCHEMBL464783 1.00 PTAFR (1.00) PTAFRGLRA1GLRA2CYP2C9HSD17B10
Ginkolide B SCHEMBL14029435 1.00 PTAFR (1.00) PTAFRGLRA1GLRA2CYP2C9HSD17B10
Ginkolide B SCHEMBL29410795 1.00 PTAFR (1.00) PTAFRGLRA1GLRA2CYP2C9HSD17B10
Ginkolide B SCHEMBL14279903 1.00 PTAFR (1.00) PTAFRGLRA1GLRA2CYP2C9HSD17B10
SCHEMBL13960075 0.94 PTAFR (0.89) PTAFRGLRA1GLRA2CYP2C9HSD17B10
SCHEMBL13702667 0.94 PTAFR (0.89) PTAFRGLRA1GLRA2CYP2C9HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4088723-B1 CANNABIDIOL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF CHENGDU BAIYU PHARMACEUTICAL CO LTD (CN) 2025-08-06 EP claimed
EP-4031182-A1 ENDOCANNABINOID MIMETIC AND ANTI-INFLAMMATORY COMPOUND CONTAINING COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF Pharma Cosmetix Research, LLC (US) 2022-07-27 EP claimed
US-20220202739-A1 ENDOCANNABINOID MIMETIC AND ANTI-INFLAMMATORY COMPOUND CONTAINING COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF PHARMA COSMETIX RES LLC (US) 2022-06-30 US claimed
EP-3958973-B1 COMPOSITIONS FOR USE IN METHODS FOR IMPROVING SHORT-TERM MEMORY CYTOSOLVE INC (US) 2026-04-15 EP disclosed
US-20260071239-A1 COMPOSITIONS AND METHODS FOR IMPROVED CELL CULTURE EFFICIENCY AMYRIS INC (US) 2026-03-12 US disclosed
EP-4705495-A2 METHODS FOR IMPROVED CELL CULTURE PERFORMANCE AND PRODUCT RECOVERY Amyris, Inc. (US) 2026-03-11 EP disclosed
US-12521365-B2 Compositions for improving brain health and memory CYTOSOLVE, INC. (US) 2026-01-13 US disclosed
US-12516090-B2 Maltose dependent degrons, maltose-responsive promoters, stabilization constructs, and their use in production of non-catabolic compounds Amyris, Inc. (US) 2026-01-06 US disclosed
US-20250368590-A1 COMPOSITIONS AND METHODS FOR THE PURIFICATION OF ISOPRENOIDS AMYRIS INC (US) 2025-12-04 US disclosed
US-12473556-B2 Methods for stabilizing production of acetyl-coenzyme a derived compounds Amyris, Inc. (US) 2025-11-18 US disclosed
US-12439922-B2 Plant-based chemicals for Varroa mite control BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2025-10-14 US disclosed
WO-2022043407-A1 COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS LAOUAREM YOUSRA (FR) 2022-03-03 WO disclosed
EP-3958973-A1 COMPOSITIONS FOR IMPROVING BRAIN HEALTH AND MEMORY Cytosolve, Inc. (US) 2022-03-02 EP disclosed
US-11230716-B2 Methods for stabilizing production of acetyl-coenzyme A derived compounds Amyris, Inc. (US) 2022-01-25 US disclosed
CN-111171043-B Method for extracting ginkgolide B 克拉玛依市人民医院 2020-10-30 CN disclosed
CN-111171043-A Method for extracting ginkgolide B 克拉玛依市人民医院 2020-05-19 CN disclosed
WO-2017133517-A1 PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF 四川海思科制药有限公司 2017-08-10 WO disclosed
WO-2016066100-A1 PHARMACEUTICAL COMPOSITION CONTAINING GINKGOLIDE B AND ADP RECEPTOR ANTAGONIST, PREPARATION METHOD THEREOF AND USE THEREOF 成都百裕科技制药有限公司 2016-05-06 WO disclosed
WO-2016066128-A1 PHARMACEUTICAL COMPOSITION CONTAINING GINKGOLIDE B AND XA FACTOR INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF 成都百裕科技制药有限公司 2016-05-06 WO disclosed
US-20110086119-A1 Preparation for the relief of disease AKL TECHNOLOGIES LIMITED 2011-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260071239-A1 COMPOSITIONS AND METHODS FOR IMPROVED CELL CULTURE EFFICIENCY RHOA, NFATC1, CYP46A1 PTAFR 2044/4885GLRA1 4756/4885GLRA2 4735/4885
US-12439922-B2 Plant-based chemicals for Varroa mite control VARS1, CAT, API5 PTAFR 4751/4885GLRA1 2448/4885GLRA2 2438/4885
US-20110086119-A1 Preparation for the relief of disease F2, PLA2G7, ALOX15B PTAFR 31/4885GLRA1 2293/4885GLRA2 3029/4885
US-20250368590-A1 COMPOSITIONS AND METHODS FOR THE PURIFICATION OF ISOPRENOIDS GGPS1, HMGCR, DHCR7 PTAFR 3632/4885GLRA1 4014/4885GLRA2 3817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.